# A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

> **NCT03933735** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 220 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** TNB-383B

## Key facts

- **NCT ID:** NCT03933735
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-24
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03933735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03933735, "A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03933735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*